Imaging-guided synergistic targeting-promoted photo-chemotherapy against cancers by methotrexate-conjugated hyaluronic acid nanoparticles

A combination of chemotherapy and photothermal therapy (PIT) against cancer, overcoming the intrinsic limitations of single-modal chemotherapy or PIT, has emerged as a promising strategy to achieve synergistic therapeutic effect. However, the lack of precise drug delivery and intelligent drug release based on photo-chemotherapy at specific tumor sites remained a challenge. Hence, the both tumor-specific targeting molecule (methotrexate) and ligand (hyaluronic acid)-introduced, glutathione-responsive amphiphiles (deoxycholic acid-hyaluronic acid-methotrexate, DA-SS-HA-MTX) were developed for synchronous delivery of indocyanine green (ICG) and doxorubicin (DOX). The as-synthesized DOX/ICG@DSHM remarkably improved the intracellular drug uptake and accumulation owing to both the CD44/folate receptors-mediated synergistic targeting and the glutathione-triggered rapid drug release. Moreover, DOX/ICG@DSHM efficiently accumulated at the tumor sites, realizing the notable tumor ablation under the guidance of dual-modal optical imaging. Taken together, this study provided a promising nanotheranostic agent for imaging-guided chemo-photothermal combination therapy.